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doi:10.1016/j.ejvs.2010.08.009Abstract Objective: To investigate the efficacy of daptomycin and rifampin either alone or
in combination in preventing prosthesis biofilm in a rat model of staphylococcal vascular graft
infection.
Design: Prospective, randomised, controlled animal study.
Materials: Graft infections were established in the back subcutaneous tissue of adult male
Wistar rats by implantation of Dacron prostheses followed by topical inoculation with
2 107 colony forming units of Staphylococcus aureus, strain Smith diffuse.
Methods: The study included a control group, a contaminated group that did not receive any
antibiotic prophylaxis and three contaminated groups that received intra-peritoneal daptomy-
cin, rifampin-soaked graft and daptomycin plus rifampin-soaked graft, respectively. Each
group included 15 animals. The infection burden was evaluated by using sonication and quan-
titative agar culture. Moreover, an in vitro antibiotic susceptibility assay for S. aureus biofilms
was performed to elucidate the same activity.
Results: When tested alone, daptomycin and rifampin showed good efficacies. Their combina-
tion showed efficacies significantly higher than that of each single compound. The in vitro
studies showed that Minimum Inhibitory Concentration and Minimum Bactericidalttie Infettive, c/o Ospedali Riuniti, via Conca 71, 60126 Ancona, Italy. Tel.: þ39 071 5963715; fax:þ39
rfree.it, o.cirioni@univpm.it (O. Cirioni).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
818 O. Cirioni et al.Concentration values for daptomycin were lower in presence of rifampin. Daptomycin pre-
vented the emergence of rifampin resistance.
Conclusion: Daptomycin is an important candidate for prevention of staphylococcal biofilm-
related infection and rifampin could serve as an interesting anti-staphylococcal antibiotic
enhancer.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Medical device-associated infections often results in a poor
clinical outcome with higher short-term mortality rates,
despite recent progress in anti-microbial therapy and surgical
techniques.1,2 Gram-positive cocci, such as Staphylococcus
aureus, are frequently isolated and among these, methicillin-
resistant S. aureus (MRSA) bacteraemia is associated with
significantlyhighermortality rates thanothermicrobes.3,4 The
most important factor in the pathogenesis of these infections
is the formation of adherent, multi-layered bacterial bio-
film.5e7 Antibiotic therapy and prophylaxis to treat bacterial
biofilm infection often fail because of the capacity of the
bacteria encased into the biofilm matrix to be more resistant
to treatment when compared to planktonic bacteria.5,8
Glycopeptides are the mainstay of treatment for device-
related infections ofMRSA strains. These antibiotics havebeen
used successfully to treat infections with drug-resistant
isolates of S. aureus for more than three decades. The drugs
have their limitations, as S. aureus isolates with intermediate
resistance to vancomycin (vancomycin-intermediate S. aureus
(VISA)) have now been reported in Japan, the USA, South
America and many European countries including the UK.9,10 In
recent years, the threat of increasing glycopeptide resistance
in the global S. aureus population has led to the development
of novel antibiotics for the potential treatment of staphylo-
coccal infections. Several compounds have been evaluated in
many in vitro biofilm models.10e13 Data consistently demon-
strate suppression of bacterial growth in a biofilm but none of
the compounds significantly eradicate bacterial colonisation.
Generally, the compounds did not demonstrate significant
activity in established biofilms due to either a lack of pene-
tration, drug inactivation or the state of bacterial cell division
within thebiofilm.5,7,14 Promising agents shouldpenetrate into
the biofilm extracellular layer and have bactericidal activity
irrespective of the bacteria’s physiological state and also
prevent further biofilm formation. Lipopeptides, such as dap-
tomycin, display rapid bactericidal activity against staphylo-
cocci, irrespective of the bacterial growth phase.15e17 This
compound also demonstrates the ability to successfully
penetrate into congealed bacterial masses, such as the vege-
tations formed in endocardial infections.6,16
In the present study, we have investigated the efficacy
of daptomycin and rifampin alone or combined in pre-
venting prosthesis biofilm in a rat model of staphylococcal
vascular graft infection.
Materials and Methods
Organisms
Methicillin-susceptible (MS) S. aureus, strain Smith diffuse,
kindly provided by Dr N. Balaban (Department of Biomedical
Sciences, Division of Infectious Diseases, School of VeterinaryMedicine, Tufts University, North Grafton, MA 01536, USA),
wasused.This is a highly encapsulated, slime-producing strain
with exopolysaccharides which are antigenically identical to
many clinical S. aureus strains tested. Five MS S. aureus clin-
ical strains were used for interaction studies.
Anti-microbial agents
Preparation of sterile stock solutions of daptomycin (Novartis
Italia S.p.A, Varese, Italy) and rifampin (SigmaeAldrich,
Milan, Italy) was performed according to the manufacturer’s
instructions. The antibiotic concentrations used in these
experiments corresponded to daptomycin plasma concen-
trations achievable in humans (16).
Adherent biofilm formation for susceptibility
testing
To develop biofilms, 50 ml of Triptic Soy broth (TSB) (Oxoid
S.p.A., Milan, Italy) containing 106 Colony Forming Unit (CFU)
ml1 of bacteria were added under aseptic conditions to each
well of a tissue culture-treated polystyrene 96-well plate Bec-
ton and Dickinson Italia S.p.A., Bd, Buccinasco (MI), Italy con-
taining 150 ml of TSB-2% glucose. After a 24-h incubation at
37 C, the growth medium was discarded and each well was
washed three times with phosphate-buffered saline (PBS)
under aseptic conditions to eliminate unbound bacteria. To
evaluate the formation of adherent biofilm, the remaining
attached bacteria were fixed with 0.2 ml of 99% methanol per
well, and 15 min later, the plates were emptied and left to dry.
The plateswere then stained for 5 minwith 0.2 ml of 2% crystal
violet used for Gram staining per well. The excess stain was
rinsedoff byplacing theplateunder running tapwater.18,19 The
plates were air-dried and the dye bound to the adherent cells
was resolubilised with 0.2 ml of 33% volume to volume (v/v)
glacial acetic acid per well. The optical density (OD) of each
wellwasdeterminedphotometrically at 570 nmbyusing theMR
700 Microplate Reader (Dynatech Laboratories, Guernsey, UK).
The 0.00 value (negative control) was determined for every
plate measuring the OD of a well filled with PBS solution. The
cut-off OD for the microtitre-plate test was defined as three
standarddeviationsabove themeanODof thenegativecontrol.
The same experiment was performed three times: (i) with and
(ii) without addition of 10 mg of rifampin in Mueller-Hinton (MH)
(Mueller-Hinton, Oxoid S.p.A., Milan Italy) broth in each well.
Tests were performed in triplicate. Biofilmswere also observed
by lights microscopy with the tests performed in duplicate.
Susceptibility testing with adherent cells
For use in the biofilm test, the Minimum Inhibitory Concen-
tration (MIC) and Minimum Bactericidal Concentration
Prophylaxis and Vascular Graft Infection 819(MBC), respectively were determined with modifications.
Biofilms were washed with PBS in order to discard unbound
bacteria. Subsequently, serial twofold dilution of antibiotic
in MH broth was added to wells containing adherent organ-
isms. The polystyrene plateswere incubated for 18 h at 37 C
in air. The MIC was taken as the lowest daptomycin concen-
tration at which observable growth was inhibited. To deter-
mine the MBC, the MH broth containing rifampin was
removed from each well and replaced with antibiotic-free
MHbroth; the plateswere incubated again for 18 h at 37 C in
air. The MBC was taken as the lowest concentration of dap-
tomycin that resulted in no bacterial growth following
removal of thedrug.20 In addition, to investigate theeffect of
rifampin pre-treatment on bacterial antibiotic suscepti-
bility, MIC and MBC were determined after pre-treatment of
cells for 30 minwith 10mg rifampin in 10ml MH broth perwell.
Susceptibility testing with planktonic bacteria
MICs and MBCs were determined according to the proce-
dures outlined by the Clinical and Laboratory Standards
Institute (CLSI).21 For daptomycin, the growth media was
supplemented with Ca2þ to a final concentration of
50 mg ml1. Experiments were performed in triplicate.
Synergy studies
In interaction studies, the Smith diffuse staphylococcal
strain plus five other clinical strains of S. aureus, were used
to test the antibiotic combinations by a checkerboard
titration method by using 96-well polypropylene microtiter
plates. The fractionary inhibitory concentration (FIC) index
for combinations of two anti-microbials was calculated
according to the equation: FIC indexZ FICAþ FICBZ A/
MICAþ B/MICB, where A and B are the MICs of drug A and
drug B in the combination, MICA and MICB are the MICs of
drug A and drug B alone, and FICA and FICB are the FICs of
drug A and drug B. The FIC indexes were interpreted as
follows: <0.5, synergy; 0.5e4.0, indifferent and >4.0,
antagonism.22
Animals
Adult male Wistar rats (weight range, 280e330 g) were used
for all the experiments. The study was approved by the
Animal Research Ethics Committee of the I.N.R.C.A.
I.R.R.C.S., University of Ancona, Italy.
Rat model
The in vivo study included a control group (no graft
contamination), a contaminated group that did not receive
any antibiotic prophylaxis and three contaminated groups
that received intra-peritoneal daptomycin (6 mg kg1),
rifampin-soaked graft and intra-peritoneal daptomycin
(6 mg kg1) plus rifampin-soaked graft, respectively. Each
group included 15 animals and, to verify the results, the
experiments were performed in duplicate. In the statistical
analysis, the data were merged and referred to all 30
animals from each pair of groups. Rats were anaesthetised
with ether, the hair on the back was shaved and the skincleansed with 10% povidoneeiodine solution. Immediately
before the surgical procedure, each group received a single
dose of the above-mentioned compounds intra-peritoneally
at the established dosages. One subcutaneous pocket was
made on each side of the median line by a 1.5-cm incision.
Aseptically, 1 cm2 sterile collagen-sealed polyester vascular
grafts were implanted into the pockets. In the groups
locally treated with the antibiotic-soaked graft, the binding
was obtained immediately before implantation by soaking
grafts for 30 min in a sterile solution of the 10 mg l1
rifampin. The pockets were closed by means of skin clips
and a saline solution (1 ml) containing 2  107 CFU ml1
staphylococcal strain was inoculated on to the graft surface
using a tuberculin syringe to create a subcutaneous fluid-
filled pocket. Immediately before the surgical procedure,
two groups received a single dose of the established dosage
of daptomycin intra-þperitoneally. The animals were
returned to their individual cages and thoroughly examined
daily. Based on experiments demonstrating peak bacterial
growth and biofilm formation within 72 h (data not shown),
all grafts were explanted at 7 days following implantation.
Toxicity was evaluated on the basis of the presence of any
drug-related adverse effects, that is, local signs of perigraft
inflammation, anorexia, weight loss, vomiting, diarrhoea,
fever and behavioural alterations.
Assessment of the infection
The explanted grafts were placed in sterile tubes, washed
in sterile saline solution, placed in tubes containing 10 ml of
PBS solution and sonicated for 2 min to remove the
adherent bacteria from the grafts. Quantisation of viable
bacteria was performed by culturing serial 10-fold dilutions
(0.1 ml) of the bacterial suspension on blood agar plates.
All plates were incubated at 37 C for 48 h and evaluated
for the presence of the staphylococcal strain. The organ-
isms were quantitated by counting the number of CFU per
plate. The limit of detection for this method was approxi-
mately 10 CFU ml1.
Emergence of anti-microbial resistance in vivo
Positive cultures of samples from explanted grafts were
screened for the in vivo emergence of resistance to
rifampin and daptomycin. The bacteria were incubated at
35 C in 10 ml of MH broth until turbid and the turbidity of
the cultures were adjusted to match an OD of 1.25 at
550 nm, corresponding to approximately 109 CFU ml1.
Successively, aliquots (0.1 ml) were treated with seven
consecutive cycles of dilution 1/100 in fresh, drug-free MH
broth and overnight incubation at 37 C. Finally, each strain
was re-tested for susceptibility to each antibiotic by the
microbroth dilution method.
Statistical analysis
MIC values are presented as the geometric mean of three
separate experiments. Quantitative culture results of the
in vivo experiments were presented as mean SD. of
the mean and the statistical comparisons between the
groups, made by using analysis of variance (ANOVA) on
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Significant Difference Test. Significance was accepted
when the P-value was 0.05.
Results
In vitro studies
The production of the biofilm was photometrically
confirmed: the strain showed a mean OD570 nm of
0.712 0.051. Daptomycin against the adherent bacteria
without rifampin showed MIC and MBC values of 4.00 and
16.00 mg l1. In contrast, daptomycin in the presence of
rifampin showed MICs (1.00 mg l1) and MBCs (4.00 mg l1)
that were fourfold lower (Table 1).
When MICs and MBCs were determined according to the
procedures outlined by the CLSI the experiments showed
values four to eight times lower.
In the combination studies, synergy was observed when
daptomycin was combined with rifampin for all the staph-
ylococcal strains tested (range 0.187e0.385). (Table 2).
In vivo studies
None of the animals included in the uncontaminated
control group had microbiological evidence of graft infec-
tion. On the contrary, all 30 rats included in the untreated
control group demonstrated evidence of graft infection,
with quantitative culture results showing
7.4  106  2.0  106 CFU ml1.
In the rat groups treated singly, daptomycin showed the
lowest bacterial numbers (3.3 102 0.7 102 CFU ml1).
The rifampin-treated group also showed good activity and
significant differences to the control group with bacterial
numbers of 4.2 103 0.5 103 CFU ml1 (T-test,
tZ 41.98, 58 df, p< 0.001). The drug combination showed
efficacies higher than that of each single compound with
bacterial numbers of 101 CFU ml1 graft (Table 3). In the
results from quantitative bacterial graft cultures there
were always significant differences when the data obtained
from treated groups were compared with those from the
untreated groups.
The emergence of anti-microbial resistance in adherent
bacteria after rifampin monotherapy was observed in four
cases (26.6%) and showed MICs and MBCs in the range 64 e
>256 and 128e >256, respectively. This decreased suscepti-
bility was retained during seven passages in antibiotic-free
growth medium, suggesting the selection of stable rifampin-Table 1 In vitro anti-microbial activity of daptomycin
against S. aureus strain Smith adherent cells with or without
rifampin pre-treatment.
Biofilm
Agent MIC (mg/mL) MBC (mg/mL)
Daptomycin 4.00 16.00
Daptomycina 1.00 4.00
a Rifampin pre-treatment (10 mg rifampin in 10 mL MH broth/
well).resistant mutants. On the contrary, during therapy with dap-
tomycin alone or in combination with rifampin, decreased
susceptibility was never observed (data not shown).
Finally, none of the animals included in any group died
or had clinical evidence of drug-related adverse effects,
such as local signs of perigraft inflammation, anorexia,
vomiting, diarrhoea and behavioural alterations.
Discussion
The ability to form biofilm on medical devices is a potential
virulence trait that may allow staphylococci and other
Gram-positive bacteria to cause infections in the expanding
population of patients managed with such devices. All
medical devices provide a surface for bacterial colonisation
and, therefore, they become susceptible to the formation
of a persistent bacterial biofilm with increasing in-dwelling
time. This is extremely difficult to treat as it is able to resist
higher antibiotic concentrations than bacteria in suspen-
sion.1,5,23 The biofilm consists of multi-layered cell clusters
embedded in a matrix of extracellular polysaccharide
(slime), which facilitates the adherence of these micro-
organisms to biomedical surfaces and protects them from
the host immune system and anti-microbial therapy.5,6
It is well known that the surface of several synthetic
materials used by microbiologists and surgeons, such as
polyester vascular grafts, bind molecules and this property
has been evaluated and utilised during in vitro and in vivo
studies.24e27 In experimental models, if the anti-microbial
agents have an insufficient number of positively charged
residues, they are usually bound to the medical devices via
a binding compound such as collagen, albumin, fibrin and
tridodecylmethylammonium chloride. Prevention strategies
include efforts to insert implants under stringent aseptic
conditions, and also encompass the development of novel
materials which interfere with the initial attachment of
micro-organisms to the surface of the device.24,26,27
Several studies showed that rifampin is a good antibiotic
in decreasing the microbial burden of staphylococcal colo-
nisation in biofilm, but it greatly reduced its activity after
a brief exposure.15,25,28 This failure to decrease the
microbial burden of staphylococci in biofilm is often asso-
ciated with the emergence of resistant organisms when
rifampin is used alone on a daily basis. This fact heightens
concern about the need of a new rational approach for
better preventive and therapeutic strategies. One way to
overcome the problems of the emergence of resistance andTable 2 Results of interaction studies between dapto-
mycin and rifampin.
Staphylococcal Strains FIC indexes
Smith diffuse 0.385
Strain no. 2 0.312
Strain no. 3 0.187
Strain no. 4 0.312
Strain no. 5 0.385
Strain no. 6 0.385
The ranges of concentrations tested were of 0.25e256 mg/l.
Table 3 Activity of daptomycin and rifampin against Staphylococcus aureus, strain Smith diffuse (SD) in a subcutaneous rat
pouch model of infection.
Groupa Graft-bonded
drugb
Intra-peritoneal
preoperative drugc
Quantitative graft
culture (CFU/ml)d
p-value (comparison
with untreated
control group)
p-value (comparison
with double-
treated group)
uncontaminated control e <10
untreated control e 7.4  106 2.0  106
Group 1 e Daptomycin 3.3  102 0.7  102 <0.001 <0.001
Group 2 Rifampin e 4.2  103 0.5  103 <0.001 <0.001
Group 3 Rifampin Daptomycin 1.1  101 0.1  101 <0.001 <0.001
a Staphylococcus aureus, strain Smith diffuse (SD).
b The Dacron graft segments were impregnated with 10 mg/l of rifampin.
c Each rat received intra-peritoneally 6 mg/Kg of daptomycin.
d The limit of detection for the method was 10 CFU/ml.
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Gram-positive pathogens is the use of the new combination
therapy.11,15,19,29,30 Daptomycin manifests itself as a very
promising agent for its great anti-microbial activity and its
ability in inhibiting organisms embedded in biofilm.
The results obtained in this study show that the use of an
intra-peritoneal daptomycin and rifampin-soaked polyester
vascular grafts can result in significant bacterial growth
inhibition even if high concentrations of organisms are
locally inoculated in the area of prosthesis implantation.
Interestingly, daptomycin combined to rifampin completely
prevented the emergence of rifampin resistance in
adherent bacteria, while rifampin alone showed emergence
of resistance in four cases.
When tested alone both daptomycin and rifampin
showed to be effective without any toxicity and drug-
related adverse effects. The same picture was confirmed by
the in vitro studies, where the staphylococcal biofilm was
strongly affected by the presence of rifampin and in its
presence, daptomycin showed MICs and MBCs much lower
than those obtained in the absence of this compound.
Moreover the in vitro studies showed that the two antibi-
otics are synergistic. The mechanism of action of dapto-
mycin appears to involve Ca2þ-dependent binding to the
Gram-positive cell membrane, leading to channel forma-
tion, Kþ leakage and ultimately inhibition of protein and
nucleic acid synthesis.13,15 The positive interaction
between daptomycin and rifampicin could be due to the
daptomycin mechanism of action e in fact, it binds and
opens channels that can allow specific entry of rifam-
picin.31 Other studies showed that anti-microbial peptides
have a positive interaction with hydrophobic antibiotics
such as rifampicin.31 These studies showed that several
anti-microbial peptides acted synergistically with macro-
lides or tetracycline.32,33 In view of this, it is possible that
the action of a lipopeptide, such as daptomycin, at the cell
membrane could promote entry of a hydrophobic drug such
as rifampicin. Daptomycin might increase the access of the
hydrophobic antibiotics to the cytoplasmic membrane
following breakdown of peptidoglycan while, on the other
hand, it is possible that rifampin creates new sites in the
biological membranes for the lipopeptide entry. Biofilm-
associated infections on implanted medical devices are
difficult to resolve with anti-microbial chemotherapy sincethe antibiotic may have difficulty in penetrating the bio-
film. However, recent in vitro studies showed that both
daptomycin and rifampin were able to penetrate staphy-
lococcal biofilm, although their relative effective diffu-
sivity should be further evaluated.34e36
In our prophylactic study, the good anti-microbial
activities as well as the properties that affect biofilm
formation, suggest that daptomycin may be considered an
important candidate for prevention of staphylococcal bio-
film-related infection. Rifampin could serve as an inter-
esting anti-staphylococcal antibiotic enhancer.
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